We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Clorox
CLX
$12.7B
| $44.2M | 0.1% |
315,792
-12,691
| -4% | -$1.81M |
|
252
Brunswick
BC
$5.28B
| $44M | 0.1% |
691,071
+212,199
| +44% | +$15.6M |
|
253
American Tower
AMT
$80.4B
| $43.9M | 0.1% |
173,395
-151,844
| -47% | -$38.1M |
|
254
CNO Financial Group
CNO
$5.1B
| $43.7M | 0.1% |
2,461,474
+1,167,962
| +90% | +$25M |
|
255
Gentex
GNTX
$5.07B
| $43.5M | 0.1% |
1,583,995
-392,301
| -20% | -$11.4M |
|
256
Becton Dickinson
BDX
$48.2B
| $43.3M | 0.1% |
175,609
-41,909
| -19% | -$10.6M |
|
257
Edwards Lifesciences
EW
$51.7B
| $43.1M | 0.1% |
455,722
-20,318
| -4% | -$2.1M |
|
258
General Mills
GIS
$19.7B
| $42.9M | 0.1% |
575,705
-10,232
| -2% | -$717K |
|
259
VeriSign
VRSN
$26.6B
| $42.6M | 0.1% |
255,583
+16,367
| +7% | +$3M |
|
260
Jack Henry & Associates
JKHY
$11.1B
| $42.6M | 0.1% |
236,496
+1,418
| +0.6% | +$266K |
|
261
Playtika
PLTK
$1.12B
| $42.3M | 0.1% |
3,198,143
+2,341,243
| +273% | +$36.5M |
|
262
Valero Energy
VLO
$85.9B
| $42.3M | 0.1% |
397,874
+252,602
| +174% | +$29.9M |
|
263
Crown Castle
CCI
$32.2B
| $42.2M | 0.1% |
250,834
-230,230
| -48% | -$41.9M |
|
264
Macy's
M
$6.68B
| $42.1M | 0.1% |
2,331,255
-323,726
| -12% | -$7.32M |
|
265
Pinduoduo
PDD
$131B
| $42M | 0.09% |
679,608
-54,407
| -7% | -$2.55M |
|
266
SS&C Technologies
SSNC
$18.6B
| $41.8M | 0.09% |
729,676
+64,553
| +10% | +$4.15M |
|
|
TPH
267
DELISTED
Tri Pointe Homes
TPH
| $41.6M | 0.09% |
2,536,331
+231,567
| +10% | +$4.54M |
|
268
Greif
GEF
$5.04B
| $41.4M | 0.09% |
674,487
+80,186
| +13% | +$4.9M |
|
269
Whirlpool
WHR
$2.82B
| $41.3M | 0.09% |
271,579
+98,086
| +57% | +$17.1M |
|
270
HCA Healthcare
HCA
$89.5B
| $41M | 0.09% |
245,469
+43,251
| +21% | +$9.29M |
|
271
Omnicom Group
OMC
$23.4B
| $40.8M | 0.09% |
651,855
-101,857
| -14% | -$7.54M |
|
272
Westlake Corp
WLK
$9.9B
| $40.6M | 0.09% |
413,936
-110,662
| -21% | -$13.6M |
|
273
Exelixis
EXEL
$13.4B
| $40.5M | 0.09% |
1,964,719
+1,089,169
| +124% | +$22.4M |
|
274
Bunge Global
BG
$20.8B
| $40.5M | 0.09% |
446,460
+87,827
| +24% | +$9.74M |
|
275
Air Products & Chemicals
APD
$67.6B
| $40.4M | 0.09% |
171,875
-14,472
| -8% | -$3.52M |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.